KE CHENG ELECTRONIC CO., LTD.
Update：2025/01/01
Industries
Main Industry
Manufacturing
Main Product/Service
FBDB? platform
HanchorBio dedicates to develop biological medicines with simultaneous multi-targeting through a novel IgG Fc-Based Designer Biologics (FBDB?) platform. We aim to achieve the holistic effect of all participating modalities to overcome the shortcomings of the CPI therapies.
Innovative Research (Lead Discovery & Optimization)
Novel target research and evaluation
Antibody selections from hybridomas or phage library
Antibody & Protein engineering; Development of designer proteins
Development of in vitro and in vivo assays/models for evaluating the bioactivities of anti-cancer drugs
MOA studies
In Vivo Pharmacology Study
Establishment of various syngeneic, xenograft and humanized mouse models for evaluating the efficacy of anti-cancer drugs
Lab-Scale Process Development
Cell line development and RCB establishment
Cell culture process development and optimization
Purification process development and optimization
Formulation development
Assay method development
CQA, CPP determination
CMC and submission
Consideration of safety, quality and efficacy during development and CMC stages.
Scale-up, technical transfer and method transfer ability
Readiness of technical documents for filing
HanchorBio dedicates to develop biological medicines with simultaneous multi-targeting through a novel IgG Fc-Based Designer Biologics (FBDB?) platform. We aim to achieve the holistic effect of all participating modalities to overcome the shortcomings of the CPI therapies.
Innovative Research (Lead Discovery & Optimization)
Novel target research and evaluation
Antibody selections from hybridomas or phage library
Antibody & Protein engineering; Development of designer proteins
Development of in vitro and in vivo assays/models for evaluating the bioactivities of anti-cancer drugs
MOA studies
In Vivo Pharmacology Study
Establishment of various syngeneic, xenograft and humanized mouse models for evaluating the efficacy of anti-cancer drugs
Lab-Scale Process Development
Cell line development and RCB establishment
Cell culture process development and optimization
Purification process development and optimization
Formulation development
Assay method development
CQA, CPP determination
CMC and submission
Consideration of safety, quality and efficacy during development and CMC stages.
Scale-up, technical transfer and method transfer ability
Readiness of technical documents for filing
Founded Year
2023
Unified Business No.
94250830
Status
Active
Number of Employees
4
Total Paid-in
Capital
1,000,000 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, New Taipei City
Website
Exclusive content for members
Members-only content. Please log in to access.
Introduction
HanchorBio dedicates to develop biological medicines with simultaneous multi-targeting through a novel IgG Fc-Based Designer Biologics (FBDB?) platform.
